Literature DB >> 32444474

Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.

Peng Chen1, Yao Liu2, Haiyan Wang2, Guifang Liu2, Xiaojuan Lin2, Weiyan Zhang2, Feng Ji2, Qing Xu2, Zexin Tao3, Aiqiang Xu3.   

Abstract

The Polio Endgame Strategy 2019-2023 has been developed. However, more effective and efficient surveillance activities should be conducted with the preparedness of emergence for vaccine-derived poliovirus (VDPV) or wild poliovirus (WPV). We reviewed the impact of the case-based acute flaccid paralysis (AFP) surveillance (1991 to 2018) and environmental surveillance (2011 to 2018) in polio eradication in Shandong province of China. Clinical characteristics of AFP cases and enterovirus (EV) investigation of research samples were assessed. During the period, 10,224 AFP cases were investigated, and 352 sewage samples were collected. The nonpolio AFP rate sustained at over 2.0/100,000 since 1997. Of 10,224 cases, males and young children experienced a higher risk of severe diseases, and 68.5% suffered lower limb paralysis. We collected 1,707 EVs from AFP cases, including 763 polioviruses and 944 nonpolio enteroviruses (NPEVs). No WPV was isolated since 1992. The AFP surveillance showed high sensitivity in detecting 143 vaccine-associated paralytic poliomyelitis (VAPP) cases and 6 VDPVs. For environmental surveillance, 217 (61.6%) samples were positive for poliovirus, and altogether, 838 polioviruses and 2,988 NPEVs were isolated. No WPV was isolated in environmental surveillance, although one VDPV2 was identified. Phylogenetic analysis revealed environmental surveillance had the capacity to detect a large scope of NPEVs. The case-based AFP surveillance will be indispensable for detecting VAPP cases and VDPV circulation in countries using oral polio vaccine. Environmental surveillance is advantageous in identifying EV circulation and responding to ongoing circulating VDPV outbreaks and should be expanded to complement the AFP surveillance.IMPORTANCE Interrupting wild poliovirus transmission and stopping circulating vaccine-derived poliovirus (cVDPV) outbreaks have been proposed as two global goals by the World Health Organization in the Global Polio Eradication Initiative (GPEI). This analysis, based on the 28-year acute flaccid paralysis (AFP) surveillance and 8-year environmental surveillance, provides continued high-quality surveillance performance in achieving the GPEI and detecting the circulation of enterovirus. Given the ongoing cVDPV outbreaks in the world, we present the surveillance capacity of environmental surveillance in capturing enterovirus circulation. The final poliovirus (especially VDPV) elimination has become increasingly complex, and the case-based AFP surveillance alone will lead to difficulties in early detecting dynamics of poliovirus transmission and monitoring the extent of environmental circulation. This study goes beyond previous work to provide a detailed comprehensive evaluation of the enterovirus surveillance and can be used to formulate a set of implementation plan and performance indicators for environmental surveillance.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  acute flaccid paralysis surveillance; enterovirus; environmental surveillance; oral polio vaccine; poliomyelitis

Mesh:

Year:  2020        PMID: 32444474      PMCID: PMC7376550          DOI: 10.1128/AEM.00702-20

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  29 in total

1.  Surveillance for polio eradication in the People's Republic of China.

Authors:  J Zhang; L B Zhang; M W Otten; T Jiang; X L Zhang; R Z Zhang; K A Wang
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

2.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0.

Authors:  Koichiro Tamura; Glen Stecher; Daniel Peterson; Alan Filipski; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2013-10-16       Impact factor: 16.240

3.  Insidious reintroduction of wild poliovirus into Israel, 2013.

Authors:  E Anis; E Kopel; S R Singer; E Kaliner; L Moerman; J Moran-Gilad; D Sofer; Y Manor; L M Shulman; E Mendelson; M Gdalevich; B Lev; R Gamzu; I Grotto
Journal:  Euro Surveill       Date:  2013-09-19

4.  Isolation of a recombinant type 3/type 2 poliovirus with a chimeric capsid VP1 from sewage in Shandong, China.

Authors:  Zexin Tao; Haiyan Wang; Aiqiang Xu; Yong Zhang; Lizhi Song; Shuangli Zhu; Yan Li; Dongmei Yan; Guifang Liu; Hiromu Yoshida; Yao Liu; Lei Feng; Toru Chosa; Wenbo Xu
Journal:  Virus Res       Date:  2010-03-03       Impact factor: 3.303

5.  Intercity spread of echovirus 6 in Shandong Province, China: application of environmental surveillance in tracing circulating enteroviruses.

Authors:  Zexin Tao; Yanyan Song; Haiyan Wang; Yong Zhang; Hiromu Yoshida; Shengxiang Ji; Aiqiang Xu; Lizhi Song; Yao Liu; Ning Cui; Feng Ji; Yan Li; Peng Chen; Wenbo Xu
Journal:  Appl Environ Microbiol       Date:  2012-07-27       Impact factor: 4.792

6.  An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China.

Authors:  Yong Zhang; Xiao-Juan Tan; Hai-Yan Wang; Dong-Mei Yan; Shuang-Li Zhu; Dong-Yan Wang; Feng Ji; Xian-Jun Wang; Yong-Jun Gao; Li Chen; Hong-Qiu An; De-Xin Li; Shi-Wen Wang; Ai-Qiang Xu; Zi-Jun Wang; Wen-Bo Xu
Journal:  J Clin Virol       Date:  2009-03-09       Impact factor: 3.168

7.  Non-polio enteroviruses from acute flaccid paralysis surveillance in Shandong Province, China, 1988-2013.

Authors:  Zexin Tao; Haiyan Wang; Yao Liu; Yan Li; Ping Jiang; Guifang Liu; Xiaojuan Lin; Manshi Li; Suting Wang; Feng Ji; Lei Feng; Ping Xiong; Yan Zhang; Yi Feng; Qingying Fan; He Yang; Jing Yang; Peng Chen; Wenfeng Li; Aiqiang Xu; Lizhi Song
Journal:  Sci Rep       Date:  2014-08-22       Impact factor: 4.379

8.  Twenty-nine Cases of Enterovirus-D68-associated Acute Flaccid Myelitis in Europe 2016: A Case Series and Epidemiologic Overview.

Authors:  Marjolein Knoester; Jelte Helfferich; Randy Poelman; Coretta Van Leer-Buter; Oebele F Brouwer; Hubert G M Niesters
Journal:  Pediatr Infect Dis J       Date:  2019-01       Impact factor: 2.129

9.  Progress Toward Polio Eradication - Worldwide, January 2017-March 2019.

Authors:  Sharon A Greene; Jamal Ahmed; S Deblina Datta; Cara C Burns; Arshad Quddus; John F Vertefeuille; Steven G F Wassilak
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-05-24       Impact factor: 17.586

10.  Update on Vaccine-Derived Poliovirus Outbreaks - Democratic Republic of the Congo and Horn of Africa, 2017-2018.

Authors:  Chukwuma Mbaeyi; Mary M Alleman; Derek Ehrhardt; Eric Wiesen; Cara C Burns; Hongmei Liu; Raimi Ewetola; Lerato Seakamela; Rennatus Mdodo; Modjirom Ndoutabe; Pierre Kandolo Wenye; Yogolelo Riziki; Peter Borus; Christopher Kamugisha; Steven G F Wassilak
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-03-08       Impact factor: 17.586

View more
  3 in total

1.  Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018-2019.

Authors:  Hehe Zhao; Xiaozhen Ma; Haishu Tang; Yong Zhang; Na Chen; Wusiman Kaisaier; Qi Wang; Cheng Wang; Shuangli Zhu; Qi Qi; Yu Liu; Qianli Ma; Qing Yang; Junhan Li; Dongyan Wang; Xiaolei Li; Jinbo Xiao; Hui Zhu; Wenbo Xu; Wenbin Tong; Dongmei Yan
Journal:  Open Forum Infect Dis       Date:  2021-10-17       Impact factor: 3.835

2.  Early identification of a COVID-19 outbreak detected by wastewater surveillance at a large homeless shelter in Toronto, Ontario.

Authors:  Samantha Akingbola; Reisha Fernandes; Susan Borden; Kimberley Gilbride; Claire Oswald; Sharon Straus; Amir Tehrani; Janis Thomas; Rebecca Stuart
Journal:  Can J Public Health       Date:  2022-09-26

3.  Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama.

Authors:  Magda Rojas-Bonilla; Angela Coulliette-Salmond; Hanen Belgasmi; Kimberly Wong; Leanna Sayyad; Everardo Vega; Fabian Grimoldi; M Steven Oberste; Ricardo Rüttimann
Journal:  Viruses       Date:  2021-07-13       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.